According to Wallstreetcn, the U.S. Food and Drug Administration (FDA) approved Elevar's Lirafugratinib for the treatment of cholangiocarcinoma.
Article
AI TRENDS | FDA Approves Elevar's Lirafugratinib for Cholangiocarcinoma Treatment
--・
Disclaimer: Includes third-party opinions. No advice. Binance AI may be used without guarantee. See T&Cs.